The place of PD-1 inhibitors in melanoma management
Mené sur 540 patients atteints d'un mélanome métastatique réfractaire à l'ipilimumab, cet essai randomisé international de phase II évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité du pembrolizumab
Outcomes for patients with advanced melanoma have improved greatly in recent years. Pivotal to these improvements has been increased understanding of the role of immune checkpoint inhibition to potentiate anti-tumour immunity. The use of the CTLA-4 inhibitor ipilimumab, and PD-1 receptor inhibitors (pembrolizumab and nivolumab) as monotherapy, and recently nivolumab in combination with ipilimumab, have led to significant improvements in outcomes important to patients—ie, tumour control and survival.
The Lancet Oncology , commentaire, 2014